Results 111 to 120 of about 45,197 (186)

Dose Adjustment of Poly (ADP‑Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment. [PDF]

Drug Des Devel Ther, 2022
Zhao D, Long X, Wang J.
europepmc   +1 more source

Harnessing benzamides as plant stress inhibitors, growth promoters and in management of crop resilience—A review

Plant Biology, EarlyView.
Benzamides boost crop resilience by inhibiting poly(ADP‐ribose) polymerase (PARP) to enhance stress tolerance and, through their antimicrobial, herbicidal, and insecticidal derivatives, they offer broad protection for sustainable crop improvement. Abstract Benzamides have emerged as potent stress inhibitors and growth promoters in plant biotechnology ...
M. J. Koetle, T. E. Motaung, S. O. Amoo
wiley   +1 more source

Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review. [PDF]

Oncologist
Swearingen A, Audu B, Hamidu A, Mustapha A, Oguntayo A, Yahya A, Bello A, Butler R, Halliday D, Bowe S, Jordan S, Hew K, Pinto A, Castillo RP, Reis IM, George S, Schlumbrecht M.   +16 more
europepmc   +1 more source

ShallowHRD status acts as an effective prognostic predictor in ovarian cancer patients treated by poly (ADP-ribose) polymerase inhibitors (PARPis). [PDF]

J Cancer Res Clin Oncol, 2023
Guo Y, He X, Tan Y, Liu J, Chen H, Huang Y, Zhang C, Tao Y, Chen S.   +8 more
europepmc   +1 more source

Of mice and men—The emerging oral–gut–brain axis of health and disease

Periodontology 2000, EarlyView.
Abstract Objectives Oral health's inextricable links to systemic health are highlighted by the emerging oral–gut–brain axis and other well‐known axes. There is growing evidence of a complex oral–gut–brain axis linking mouth and gut microbiomes with the central nervous system.
Yvonne L. Hernandez‐Kapila, Daniel J. Weisenberger   +1 more
wiley   +1 more source

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience. [PDF]

Gynecol Oncol Rep
Amondarain Amenabar N, Mujika Eizmendi K, Gabirondo Amenabar L, Crespo Cruz M, Muñagorri Quiles I, Gutiérrez San José E, García Álvarez M, Arrondo Arizmendi I, Bengoa Fernández N, Martínez Amorena J, Sánchez Urrestarazu M, Egaña Otaño L, Churruca Galaz C.   +12 more
europepmc   +1 more source

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair. [PDF]

Signal Transduct Target Ther, 2023
Peng X, Wang Y, Zhang S, Tao Z, Dai Y, Claret FX, Elkabets M, Lin HW, Chen ZS, Kong D.   +9 more
europepmc   +1 more source

VEGF inhibitor‐induced vascular dysfunction involves redox‐sensitive PARP activation and SIRT1 disruption

Experimental Physiology, EarlyView.
Abstract Vascular endothelial growth factor receptor (VEGFR) inhibitors are effective antiangiogenic agents used in cancer therapy. However, they are associated with cardiovascular disease, including hypertension and vascular dysfunction. The molecular mechanisms underlying these cardiovascular toxicities are unclear, but oxidative stress might be ...
Karla B. Neves, Rheure Alves‐Lopes, Augusto C. Montezano, Rhian M. Touyz   +3 more
wiley   +1 more source

Recurrence after Long-Term Use of Poly ADP-Ribose Polymerase Inhibitors Triggered by Therapy-Related Myeloid Neoplasms: A Case Report. [PDF]

Case Rep Oncol
Yamada Y, Yokoi A, Kajiyama H.
europepmc   +1 more source